On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA), ...

HFA-based metered-dose ... new inhaler is started on October 1, then write October 31 on the inhaler. This will remind you to get a new inhaler on October 31, even if the old inhaler continues to ...

Asthma inhalers are hand-held devices that allow you to inhale a dose of medication to treat asthma symptoms. There are many types of asthma inhalers. They differ in whether they're used for quick ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...

The manufacturers' reported dose per actuation for both MDIs is 108 µg of albuterol sulfate, which corresponds ... temperature on the performance of the inhalers when not allowed to return ...

A New Jersey district court correctly ruled that the patents, which cover the device’s components, were improperly listed in the FDA’s Orange Book because they don’t claim the drug’s active ingredient ...

albuterol sulfate. Amneal argued that the patents, therefore, do not meet a requirement that they claim the relevant drug. Teva made a number of arguments as to why the inhaler patents are ...

that could be applied in Arizona and the other 21 states that have stock inhaler laws allowing schools to procure, stock and administer albuterol sulfate to any child experiencing respiratory ...

that could be applied in Arizona and the other 21 states that have stock inhaler laws allowing schools to procure, stock and administer albuterol sulfate to any child experiencing respiratory ...

The news followed an investigation by POLITICO’s E&E News into climate-friendly inhalers and how drug giants are developing them to undermine competition. The pharmaceutical giant AstraZeneca ...

Despite the two formulations' tolerance to extreme temperatures, drug delivery was affected when the MDIs were tested at specific temperatures outside of the recommended range.